Angiotensin-(1-7) and the G protein-coupled receptor Mas are key players in renal inflammation

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Esteban, Vanesa ^a   Heringer Walther, Silvia ^b,c   Sterner Kock, Anja ^d   de Bruin, Ron ^e   van den Engel, Sandra ^e   Wang, Yong ^c,f   Mezzano, Sergio ^g   Egido, Jesus ^a   Schultheiss, Heinz Peter ^c   Ruiz Ortega, Marta ^a   Walther, Thomas ^c,f  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF HULL   (United Kingdom)

^g UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; CYTOKINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR MAS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO ONCOGENE PROTEINS C MAS 1; PROTO-ONCOGENE PROTEINS C-MAS-1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; INFLAMMATION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY ISCHEMIA; MOUSE; NEPHRITIS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REPERFUSION INJURY; URETER OBSTRUCTION; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; KIDNEY DISEASE; MOUSE MUTANT; PATHOLOGY;

MUS;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; CYTOKINES; INFLAMMATION; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; REPERFUSION INJURY;

EID: 65549108738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005406     Document Type: Article

References (42)

1. Schoolwerth AC, Engelgau MM, Hostetter TH (2005) A public health action plan is needed for chronic kidney disease. Adv Chronic Kidney Dis 12: 418-423.
2. Thorp ML, Eastman L, Smith DH, Johnson ES (2006) Managing the burden of chronic kidney disease. Dis Manag 9: 115-121.
3. Wolf G (2006) Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919.
4. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, et al. (2006) Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 15: 159-166.
5. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026-2033.
6. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, et al. (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48: 8-20.
7. Ferrario CM (2002) Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens 20: 805-807.
8. Ferrario CM (2003) Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Curr Hypertens Rep 5: 129-134.
9. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
10. Tallant EA, Ferrario CM, Gallagher PE (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-1566.
11. Alenina N, Baranova T, Smirnow E, Bader M, Lippoldt A, et al. (2002) Cell type-specific expression of the Mas proto-oncogene in testis. J Histochem Cytochem 50: 691-696.
12. Jackson TR, Blair LA, Marshall J, Goedert M, Hanley MR (1988) The mas oncogene encodes an angiotensin receptor. Nature 335: 437-440.
13. Ambroz C, Clark AJ, Catt KJ (1991) The mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. Biochim Biophys Acta 1133: 107-111.
14. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111: 1806-1813.
15. Walther T, Balschun D, Voigt JP, Fink H, Zuschratter W, et al. (1998) Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 273: 11867-11873.
16. Walther T, Wessel N, Kang N, Sander A, Tschope C, et al. (2000) Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz J Med Biol Res 33: 1-9.
17. Klahr S, Morrissey J (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-875.
18. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, et al. (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514-1529.
19. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, et al. (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53: 937-944.
20. Satoh M, Kashihara N, Yamasaki Y, Maruyama K, Okamoto K, et al. (2001) Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 12: 317-325.
21. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJ (2005) Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 45: 138-141.
22. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, et al. (2002) Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548-1550.
23. Burgelova M, Kramer HJ, Teplan V, Thumova M, Cervenka L (2005) Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity. Kidney Int 67: 1453-1461.
24. Ferreira AJ, Pinheiro SV, Castro CH, Silva GA, Silva AC, et al. (2006) Renal function in transgenic rats expressing an angiotensin-(1-7)-producing fusion protein. Regul Pept 137: 128-133.
25. Inan MS, Razzaque MS, Taguchi T (2003) Pathological significance of renal expression of NF-kappa B. Contrib Nephrol 139: 90-101.
26. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, et al. (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21: 16-20.
27. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, et al. (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512.
28. Alcazar JM, Rodicio JL (2000) Ischemic nephropathy: clinical characteristics and treatment. Am J Kidney Dis 36: 883-893.
29. Gembardt F, Heringer-Walther S, van Esch JH, Sterner-Kock A, van Veghel R, et al. (2008) Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors. Faseb J 22: 3067-3077.
30. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, et al. (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-2363.
31. Rodgers K, Xiong S, DiZerega GS (2003) Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 51: 97-106.
32. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, et al. (2004) Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 53: 15-24.
33. Eddy AA (2005) Progression in chronic kidney disease. Adv Chronic Kidney Dis 12: 353-365.
34. Segerer S, Schlondorff D (2007) Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 27: 260-274.
35. Segerer S, Alpers CE (2003) Chemokines and chemokine receptors in renal pathology. Curr Opin Nephrol Hypertens 12: 243-249.
36. Segerer S, Nelson PJ (2005) Chemokines in renal diseases. Scientific World Journal 5: 835-844.
37. Rodriguez-Iturbe B, Johnson RJ (2006) Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 21: 260-263.
38. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, et al. (2003) Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 14: 968-980.
39. Walther T, Tschope C, Sterner-Kock A, Westermann D, Heringer-Walther S, et al. (2007) Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease. Circulation 115: 333-344.
40. Padi SS, Chopra K (2002) Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 45: 413-420.
41. Wreford NG (1995) Theory and practice of stereological techniques applied to the estimation of cell number and nuclear volume in the testis. Microsc Res Tech 32: 423-436.
42. McLachlan N, Patwardhan JR, Ayer B, Pacey NF (1994) Management of suboptimal cytologic smears. Persistent inflammatory smears. Acta Cytol 38: 531-536.